AR026356A1 - Metodo para tratar la diabetes - Google Patents

Metodo para tratar la diabetes

Info

Publication number
AR026356A1
AR026356A1 ARP000105805A ARP000105805A AR026356A1 AR 026356 A1 AR026356 A1 AR 026356A1 AR P000105805 A ARP000105805 A AR P000105805A AR P000105805 A ARP000105805 A AR P000105805A AR 026356 A1 AR026356 A1 AR 026356A1
Authority
AR
Argentina
Prior art keywords
diabetes
treat diabetes
post
treatment
prandial
Prior art date
Application number
ARP000105805A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR026356A1 publication Critical patent/AR026356A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona un método para el tratamiento de la diabetes del Tipo 2 empleando una combinacion de metformina y gliburida. También se proporciona unmétodo para el tratamiento de diabetes en pacientes sin experiencia en el fármaco empleando la formul acion anterior para reducir la resistencia a la insulinay/o la excursion de la glucosa post-prandial y/o la hemoglobina 1Ac, y/o el incremento de la insulina post-prandial, tratando así la diabetes.
ARP000105805A 1999-11-03 2000-11-03 Metodo para tratar la diabetes AR026356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (1)

Publication Number Publication Date
AR026356A1 true AR026356A1 (es) 2003-02-05

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105805A AR026356A1 (es) 1999-11-03 2000-11-03 Metodo para tratar la diabetes

Country Status (23)

Country Link
EP (1) EP1229918B1 (es)
JP (1) JP5183844B2 (es)
KR (1) KR20070089259A (es)
CN (1) CN1450902A (es)
AR (1) AR026356A1 (es)
AT (1) ATE390140T1 (es)
AU (1) AU780106B2 (es)
BR (1) BR0015294A (es)
CA (1) CA2389928C (es)
EE (1) EE05260B1 (es)
HU (1) HU229352B1 (es)
IL (1) IL149139A0 (es)
LT (1) LT5058B (es)
LV (1) LV12910B (es)
MX (1) MXPA02004282A (es)
NO (1) NO330026B1 (es)
NZ (1) NZ518278A (es)
PL (1) PL199278B1 (es)
RU (1) RU2275915C2 (es)
SK (1) SK287810B6 (es)
TW (1) TWI280125B (es)
UY (1) UY26424A1 (es)
WO (1) WO2001032157A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
EP1515701B1 (en) 2002-06-17 2014-09-17 Inventia Healthcare Private Limited Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide
WO2005046687A1 (en) * 2003-10-30 2005-05-26 Tioga Pharmaceuticals, Inc. Use of selective opiate receptor modulators in the treatment of neuropathy
TWI350751B (en) * 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
RU2387445C2 (ru) * 2004-05-03 2010-04-27 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Материалы и способы модуляции метаболизма
MY159203A (en) 2007-07-19 2016-12-30 Takeda Pharmaceuticals Co Solid preparation comprising alogliptin and metformin hydrochloride
KR101552187B1 (ko) 2007-09-10 2015-09-10 얀센 파마슈티카 엔.브이. Ｓｇｌｔ 억제제로서 유용한 화합물의 제조 방법
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP5973918B2 (ja) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト及びメチオニンを含む薬学的組成物
JP6227406B2 (ja) 2010-05-11 2017-11-08 ヤンセン ファーマシューティカ エヌ．ベー． ＳＧＬＴの阻害剤としての１−（β−Ｄ−グルコピラノシル）−２−チエニル−メチルベンゼン誘導体を含有する医薬製剤
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
BR112013019744A2 (pt) * 2011-02-02 2016-11-22 Sanofi Aventis Deutschland prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
HRP20230470T1 (hr) 2014-12-12 2023-07-21 Sanofi-Aventis Deutschland Gmbh Formulacija fiksnog omjera inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
CZ298469B6 (cs) 1997-06-18 2007-10-10 Smithkline Beecham Plc Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
ATE250418T1 (de) * 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
BR0015294A (pt) 2003-07-15
PL199278B1 (pl) 2008-09-30
JP5183844B2 (ja) 2013-04-17
SK287810B6 (sk) 2011-10-04
LT5058B (lt) 2003-09-25
LT2002063A (en) 2003-06-25
ATE390140T1 (de) 2008-04-15
NZ518278A (en) 2004-10-29
TWI280125B (en) 2007-05-01
AU780106B2 (en) 2005-03-03
NO330026B1 (no) 2011-02-07
HUP0300218A2 (hu) 2003-06-28
CA2389928A1 (en) 2001-05-10
RU2275915C2 (ru) 2006-05-10
EE200200242A (et) 2003-12-15
NO20022087D0 (no) 2002-05-02
WO2001032157A3 (en) 2002-01-24
PL364885A1 (en) 2004-12-27
HUP0300218A3 (en) 2006-02-28
HU229352B1 (en) 2013-11-28
RU2002114820A (ru) 2004-03-10
IL149139A0 (en) 2002-11-10
LV12910B (en) 2003-05-20
NO20022087L (no) 2002-06-24
CN1450902A (zh) 2003-10-22
KR20070089259A (ko) 2007-08-30
SK5002002A3 (en) 2004-05-04
MXPA02004282A (es) 2003-02-17
EP1229918A2 (en) 2002-08-14
WO2001032157A2 (en) 2001-05-10
EE05260B1 (et) 2010-02-15
AU1082601A (en) 2001-05-14
EP1229918B1 (en) 2008-03-26
UY26424A1 (es) 2001-05-31
JP2003519621A (ja) 2003-06-24
CA2389928C (en) 2010-03-23

Similar Documents

Publication Publication Date Title
AR026356A1 (es) Metodo para tratar la diabetes
UY26425A1 (es) Formulación y método antidiabético
Hamada et al. Electrical stimulation of human lower extremities enhances energy consumption, carbohydrate oxidation, and whole body glucose uptake
Feraboli-Lohnherr et al. Recovery of locomotor activity in the adult chronic spinal rat after sublesional transplantation of embryonic nervous cells: specific role of serotonergic neurons
MY155270A (en) Use of glp-1 or analogs in treatment of stroke
EA200000747A1 (ru) СПОСОБ ВВЕДЕНИЯ AspB28-ИНСУЛИНА ЧЕЛОВЕКА
BR0109336A (pt) Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico
FI3524261T3 (fi) Exendin käytettäväksi diabeteksen hoidossa ja ruumiin painon vähentämiseksi
DE60036367D1 (de) Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
ATE480256T1 (de) Plazentäre alkalische phosphatase zur diabeteskontrolle
DE50110262D1 (de) Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
DK30092A (da) Fremgangsmaade og midler til ikke-invasiv aedosis-til-virkningae administration af lipofile laegemidler
ATE409042T1 (de) Verwendung von sulodexide zur behandlung von diabetischer nephropathie
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
SE9101341D0 (sv) New medicinal use
MX2021014997A (es) Agente de vanadio y metformina como principio activo para el tratamiento de padecimientos relacionados con la resistencia a la insulina.
SU1225575A1 (ru) Способ лечени дискогенных болевых синдромов
US20030198686A1 (en) Chinese medicinal composition
RU2002109173A (ru) Способ лечения дистрофических заболеваний сетчатой оболочки глаза
KR890001555A (ko) 요산 배설용 조성물
PE20030552A1 (es) APLICACION TERAPEUTICA DE AGONISTAS SELECTIVOS DEL ESTROGENORECEPTOR BETA (ERß) PARA PROVOCAR EFECTOS SOMATOTROPOS, ORGANOTROPOS Y ANTICATABOLICOS
RU2004111044A (ru) Препарат для лечения геморрагического инсульта и способ лечения геморрагического инсульта
RU2002120168A (ru) Способ лечения ишемических заболеваний глаз

Legal Events

Date Code Title Description
FB Suspension of granting procedure